Network Pharmacology and Component Analysis Integrated Study to Uncovers the Molecular Mechanisms of Lansium parasiticum Bark Extract in Colon Cancer Treatment

Roihatul Mutiah, Malich Septi Diajeng Briliana, Ananda Rizkia Azizah Ahmad, Begum Fauziyah, Nandana Adyuta Janaloka, Arief Suryadinata


Side effects and risk of resistance are common consequences of colon cancer treatment based on chemotherapy. The medicinal plant originating in Indonesia, Lansium parasiticum bark extract (LPBE), has not been studied much. The purpose of this study is to identify the compounds present in LPBE and explain how the molecular mechanisms of the composite inhibit colon cancer cells. LC-MS/MS Liquid Chromatography Tandem Mass Spectrophotometry has been used to identify compounds in LPBE. The ADMET program is used to determine absorption profiles and bioavailability per oral. The tissue pharmacology approach uses Cytoscape 3.9.1, GeneCards, Disgenet, STRING 2.0.0, SRplot, and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway to predict the molecular anti-cancer mechanisms of these compounds. In vitro validation using PyRx Autodock Vina 9.0 and Biovia Discovery Studio with BAX (PDB ID:2YXJ), BCL2 (P DB ID:2W3L) and STAT3 receptors (PDB ID:6NJS). A total of 17 active compounds were identified through LC-MS/MS. The moronic acid compound showed the highest levels of 14.29% followed by 4-Morpholineacetic Acid 12.2% and ursolic aldehyde 8.37%. Pharmacological network analysis showed that the compounder works on the EGFR tyrosine kinase resistance path by targeting the BCL2, BAX, STAT3 genes. The results of the in silico validation support the results of tissue pharmacology findings. Ursolic aldehyde, and Moronic acid showed a higher affinity to the three receptors. Therefore, Lansium parasiticum bark extract (LPBE) is recommended for further study as a candidate anti-cancer drug both in vitro and in vivo.


Abdallah, H. M., G. A. Mohamed, and S. R. Ibrahim (2022). Lansium Domesticum—A Fruit with Multi-Benefits: Traditional Uses, Phytochemicals, Nutritional Value, and Bioactivities. Nutrients, 14(7); 1531

Berger, S. I. and R. Iyengar (2009). Network Analyses in Systems Pharmacology. Bioinformatics, 25(19); 2466–2472

Campbell, K. J. and S. W. Tait (2018). Targeting BCL-2 Regulated Apoptosis in Cancer. Open Biology, 8(5); 180002

de Castro-Carpeño, J., C. Belda-Iniesta, E. C. Sáenz, E. H. Agudo, J. F. Batlle, and M. G. Barón (2008). EGFR and Colon Cancer: A Clinical View. Clinical and Translational Oncology, 10; 6–13

Dong, J., N.-N. Wang, Z.-J. Yao, L. Zhang, Y. Cheng, D. Ouyang, A.-P. Lu, and D.-S. Cao (2018). ADMETlab: A Platform for Systematic ADMET Evaluation Based on a Comprehensively Collected ADMET Database. Journal of Cheminformatics, 10; 1–11

Douaiher, J., A. Ravipati, B. Grams, S. Chowdhury, O. Alatise, and C. Are (2017). Colorectal Cance —Global Burden, Trends, and Geographical Variations. Journal of Surgical Oncology, 115(5); 619–630

Fadhilah, K., S. Wahyuono, and P. Astuti (2021). Fractions and Isolated Compounds from Lansium Domesticum Fruit Peel Exhibited Cytotoxic Activity against T-47D and HepG2 Cell Lines. Biodiversitas Journal of Biological Diversity, 22(9); 3743–3748

Goel, V., P. Kaur, L. D. Singla, and D. Choudhury (2020). Biomedical Evaluation of Lansium Parasiticum Extract Protected Silver Nanoparticles against Haemonchus Contortus, a Parasitic Worm. Frontiers in Molecular Biosciences, 7; 595646

Ionescu, V. A., G. Gheorghe, N. Bacalbasa, A. L. Chiotoroiu, and C. Diaconu (2023). Colorectal Cancer: From Risk Factors to Oncogenesis. Medicina, 59(9); 1646

Jiang, L., J. Lu, Y. Qin, W. Jiang, and Y. Wang (2020). Anti-tumor Effect of Guava Leaves on Lung Cancer: A Network Pharmacology Study. Arabian Journal of Chemistry, 13(11); 7773–7797

Khodapasand, E., N. Jafarzadeh, F. Farrokhi, B. Kamalidehghan, and M. Houshmand (2015). Is Bax/Bcl-2 Ratio Considered As a Prognostic Marker with Age and Tumor Location in Colorectal Cancer? Iranian Biomedical Journal, 19(2); 69

Kuipers, E., W. Grady, D. Lieberman, T. Seufferlein, J. Sung, P. Boelens, C. van de Velde, and T. Watanabe (2015). Colorectal Cancer. Nature Reviews. Disease Primers., 1; 15065

Laurent-Puig, P., A. Cayre, G. Manceau, E. Buc, J.-B. Bachet, T. Lecomte, P. Rougier, A. Lievre, B. Landi, and V. Boige (2009). Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit from Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer. Journal of Clinical Oncology, 27(35); 5924–5930

Liu, F., T. Zhang, S. Zou, B. Jiang, and D. Hua (2015). B7-H3 Promotes Cell Migration and Invasion through the Jak2/Stat3/MMP9 Signaling Pathway in Colorectal Cancer. Molecular Medicine Reports, 12(4); 5455–5460

Liu, X., J. Wu, D. Zhang, K. Wang, X. Duan, and X. Zhang (2018). A Network Pharmacology Approach to Uncover the Multiple Mechanisms of Hedyotis diffusa Willd. On Colorectal Cancer. Evidence-Based Complementary and Alternative Medicine, 2018; e6517034

Lubis, M. F., H. Syahputra, D. N. Illian, and V. E. Kaban (2022). Antioxidant Activity and Nephroprotective Effect of Lansium parasiticum Leaves in Doxorubicin-Induced Rats. Journal of Research in Pharmacy, 26; 565–573

Ma, J.-h., L. Qin, and X. Li (2020). Role of STAT3 Signaling Pathway in Breast Cancer. Cell Communication and Signaling, 18; 1–13

Mutiah, R., W. S. Bhagawan, B. Ma’arif, and J. M. S. Rahmandika (2019a). Metabolite Fingerprinting Eleutherine palmifolia (L.) Merr. Using UPLC-QTOF-MS/MS. Majalah Obat Tradisional, 24(3); 139–159

Mutiah, R., M. F. Hariz, Y. Y. A. Indrawijaya, and B. Ma’arif (2019b). In Silico Prediction of Isoliquiritigenin and Oxyresveratrol Compounds to BCL-2 dan VEGF-2 Receptors. Indonesian Journal of Cancer Chemoprevention, 10(2); 51–59

Patil, V. S., S. H. Deshpande, D. R. Harish, A. S. Patil, R. Virge, S. Nandy, and S. Roy (2020). Gene Set Enrichment Analysis, Network Pharmacology and in Silico Docking Approach to Understand the Molecular Mechanism of Traditional Medicines for the Treatment of Diabetes Mellitus. Journal of Proteins and Proteomics, 11(4); 297–310

Potipiranun, T., W. Worawalai, and P. Phuwapraisirisan (2018). Lamesticumin G, a New ???? Glucosidase Inhibitor from the Fruit Peels of Lansium Parasiticum. Natural Product Research, 32(16); 1881–1886

Radha, G. and S. C. Raghavan (2017). BCL2: A Promising Cancer Therapeutic Target. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1868(1); 309–314

Rego, R., N. Foster, T. Smyrk, M. Le, M. O’connell, D. Sargent, H. Windschitl, and F. Sinicrope (2010). Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. British journal of cancer, 102(1); 165–172

Sawicki, T., M. Ruszkowska, A. Danielewicz, E. Niedźwiedzka, T. Arłukowicz, and K. E. Przybyłowicz (2021). A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis. Cancers, 13(9); 2025

Siddiqui, A. D. and B. Piperdi (2010). KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy. Annals of Surgical Oncology, 17(4); 1168–1176

Vega, P., F. Valentin, and J. Cubiella (2015). Colorectal Cancer Diagnosis: Pitfalls and Opportunities. World Journal of Gastrointestinal Oncology, 7(12); 422

Xi, Y. and P. Xu (2021). Global Colorectal Cancer Burden in 2020 and Projections to 2040. Translational Oncology, 14(10); 101174

Yang, X., Y. Tao, R. Xu, W. Luo, T. Lin, F. Zhou, L. Tang, L. He, and Y. He (2023). Analysis of Active Components and Molecular Mechanism of Action of Rubia cordifolia L. In the Treatment of Nasopharyngeal Carcinoma Based on Network Pharmacology and Experimental Verification. Heliyon, 9; e17078


Roihatul Mutiah
Malich Septi Diajeng Briliana
Ananda Rizkia Azizah Ahmad
Begum Fauziyah
Nandana Adyuta Janaloka
Arief Suryadinata (Primary Contact)
Mutiah, R., Briliana, M. S. D. ., Ahmad, A. R. A. ., Fauziyah, B., Janaloka, N. A. ., & Suryadinata, A. (2024). Network Pharmacology and Component Analysis Integrated Study to Uncovers the Molecular Mechanisms of Lansium parasiticum Bark Extract in Colon Cancer Treatment. Science and Technology Indonesia, 9(2), 314–324.

Article Details